New Weekly IcoSema Investigated for Improved Blood Sugar Control in Type 2 Diabetes
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Background
Type 2 Diabetes is a chronic metabolic condition characterized by persistently high blood sugar levels, often necessitating insulin therapy for effective management. Many individuals with Type 2 Diabetes struggle with complex daily insulin regimens, which can lead to challenges in adherence and suboptimal glycemic control. This study addresses the critical need for simplified, yet highly effective, treatment options for patients whose diabetes remains inadequately controlled with existing daily basal insulin therapies.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
